Clinical Trials Update: Dec. 27, 2006
Allergies and Asthma Menstrual Disorders Bladder Disorders
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Allergies and Asthma
This study will evaluate the safety, tolerability, and effectiveness of an experimental drug called HAE1 for people with moderate-to-severe allergic asthma. You will not qualify for this study if you are pregnant and/or breast feeding, have active lung disease other than asthma, any significant illness, or prior treatment with omalizumab and/or any beta blocker medication.
The research site is in Bronx, NY.
Women 18-49 may qualify for this study if they have had three or more days of heavy menstrual bleeding in at least four of the last six menstrual periods, periods that are 21-35 days apart and last less than 10 days, no history of uterine or cervical cancer, and have not had a hysterectomy or both ovaries removed.
The research site is in Ann Arbor, Mich.
This 16-week study will evaluate the study medication's effectiveness in treating people with overactive bladder (OAB). Volunteers at least 18 who have symptoms of OAB (such as frequency, urgency, and nighttime urination) for at least six months and have not had success with other medication(s) for OAB may be eligible.
The research site is in Gilbert, Ariz.
Copyright 2006 Thomson CenterWatch. All rights reserved.